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Summary
The melanocortin-4 receptor (MC4R) plays a critical role in the control of energy balance. Of its two pro-opiomelanocortin
(POMC)-derived ligands, a- and b-MSH, the majority of attention has focused on a-MSH, partly reflecting the absence of
b-MSH in rodents. We screened the POMC gene in 538 patients with severe, early-onset obesity and identified five unrelated
probands whowere heterozygous for a rare missense variant in the region encoding b-MSH, Tyr221Cys. This frequency was
significantly increased (p < 0.001) compared to the general UK Caucasian population and the variant cosegregated with
obesity/overweight in affected familymembers. Compared towild-type b-MSH, the variant peptidewas impaired in its ability
to bind to and activate signaling from the MC4R. Obese children carrying the Tyr221Cys variant were hyperphagic and
showed increased linear growth, both of which are features of MC4R deficiency. These studies support a role for b-MSH
in the control of human energy homeostasis.Introduction
The pro-opiomelanocortin (POMC) gene is expressed in neurons
originating in the arcuate nucleus of the hypothalamus and in the
nucleus tractus solitarius (NTS) of the caudal medulla, as well as
in the corticotrophs of the anterior pituitary and in the skin and
lymphoid system (Hadley and Haskell-Luevano, 1999). POMC
undergoes extensive and tissue-specific posttranslational pro-
cessing by proprotein convertases (PCs) to yield a range of bio-
logically active peptides (Bertagna, 1994; Pritchard et al., 2002;
Seidah and Chretien, 1999). Pituitary corticotrophs express
prohormone convertase 1 (PC1), but not PC2, resulting in the
production of N-terminal peptide, joining peptide, ACTH, and
b-lipotropin. In contrast, the expression of PC2 within the hypo-
thalamus leads to the production of a-, b-, and g-MSH (the mel-
anocortins) but not ACTH (Bertagna, 1994; Pritchard et al., 2002).
The melanocortins mediate their effects through a family of five
related G protein-coupled receptors, two of which, MC3R and
MC4R, are highly expressed within the central nervous system
(Gantz and Fong, 2003). Genetic defects impairing the synthesis
and processing of POMC and in the receptors for its constituent
melanocortin peptides have clearly established that the melano-
cortin system plays a critical role in energy homeostasis in ro-
dents and humans (Cone, 2005).CELL METABOLISM 3, 135–140, FEBRUARY 2006 ª2006 ELSEVIER INCOf the two centrally expressed melanocortin receptors, the
MC4R is the one most closely linked to energy homeostasis.
Thus, humans and mice lacking the MC4R are markedly obese
and hyperphagic as well as showing increased linear growth and
severe hyperinsulinaemia from a young age (Farooqi et al., 2003;
Huszar et al., 1997). Mice lacking the MC3R have subtle abnor-
malities of body composition, which occur later in life (Butler
et al., 2000; Chen et al., 2000), and no MC3R mutations convinc-
ingly linked to monogenic human obesity have been described.
Mutations affecting POMC have also helped to illuminate the
role of the melanocortin system in energy balance (Coll et al.,
2004). Mice (Challis et al., 2004) and humans (Krude et al.,
1998) genetically lacking all POMC-derived peptides are se-
verely obese, but their phenotype is complicated by the severe
glucocorticoid deficiency that results from the concomitant ab-
sence of ACTH. Importantly, heterozygous null POMC muta-
tions in mice (Challis et al., 2004) and humans (Krude et al.,
2003) predispose to obesity but do not necessarily result in a
severe phenotype. In contrast to the clear hierarchy of melano-
cortin receptors in the control of energy balance, there is still un-
certainty regarding the relative importance of particular POMC-
derived melanocortin ligands in these processes.
In vitro studies have established that g-MSH preferentially
binds to MC3R with a 50-fold higher affinity than to MC4R, which. DOI 10.1016/j.cmet.2006.01.006 135
S H O R T A R T I C L Eit binds to poorly (Abbott et al., 2000). In comparison, a- and
b-MSH both bind to the MC4R with high affinity and with similar
IC50 values (Abbott et al., 2000). Indeed, some studies suggest
that b-MSH has higher affinity for MC4R in stably expressing cell
lines (Schioth et al., 1996) and in rat hypothalamic homogenates
(Harrold et al., 2003). In rats, icv administration of b-MSH
induced early growth response factor-1 expression in hypotha-
lamic nuclei (Millington et al., 2001). Several in vivo studies have
demonstrated that rodents given a single intracerebroventricu-
lar (icv) injection of a-MSH display a dose-dependent reduction
in food intake (Poggioli et al., 1986). In direct comparisons of icv
administration of melanocortin peptides, b-MSH has been
shown to reduce food intake at equimolar doses (Abbott et al.,
2000). Despite this, attention has been principally focused on
a-MSH as the probable endogenous ligand in rodents (Mountjoy
and Wong, 1997). This is largely because rodents (the most
common experimental species) lack the proximal di-basic site
that is necessary for the proteolytic cleavage event that pro-
duces b-MSH in humans (mouse accession number P01193,
rat accession number AAA41903). Thus, it is possible that an im-
portant role for b-MSH in the control of energy balance has been
overlooked.
In order to determine whether missense/nonsense mutations
within the melanocortin peptides might predispose to obesity,
we screened the coding regions of the POMC gene for muta-
tions in 538 UK Caucasian subjects with severe early-onset obe-
sity in the absence of obvious glucocorticoid deficiency (mean
BMI SDS 3.86 0.9, age of onset < 5 years) using a combination
of direct sequencing and denaturing high-performance liquid
chromatography (Transgenomic WAVE DNA fragment analysis).
We also screened 300 UK Caucasian non-obese adult controls.
Results
Identification of missense mutations in POMC
We identified a number of sequence variants in POMC in se-
verely obese children (Table 1). As well as a number of synony-
mous SNPs and a common 9 bp insertion that has been re-
ported previously (Challis et al., 2002; Del Giudice et al., 2001;
Echwald et al., 1999), we identified seven rare nonsynonymous
SNPs. Three of these missense mutations directly affect regions
of the POMC gene that encode melanocortin peptides (Fig-
ure 1A). R236G was identified in three patients but also two con-
trols. We have previously shown that this mutation disrupts a di-
basic cleavage site between b-MSH and b-endorphin, resulting
in a b-MSH/ b-endorphin fusion protein that binds to MC4R but
has reduced ability to activate the receptor (Challis et al., 2002).
Its presence in both obese probands and controls reflects pre-
vious studies that show that this is not a highly penetrant cause
of inherited obesity but may increase the risk of obesity in car-
riers (Challis et al., 2002; Echwald et al., 1999). Novel heterozy-
gous missense mutations were found in b-MSH (Tyr221Cys, five
subjects) and a-MSH (His143Gln, one subject). Other mutations
were rare and/or occurred in regions of the POMC pro-peptide
of uncertain function. Our further studies concentrated on the
a- and b-MSH variants.
Tyr221Cys in b-MSH is more common in obese subjects
than in controls
A novel heterozygous missense mutation (Tyr221Cys) in b-MSH
was found in five unrelated UK Caucasian probands (Table 1).136This variant was also found in 1/300 non-obese UK Caucasian
adults. To establish the frequency of this allele in an unselected
UK Caucasian population, we genotyped a random subset
of 5000 subjects recruited to the EPIC-Norfolk study (Khaw
et al., 2001). 4,852 subjects were successfully genotyped, and
we identified 3 heterozygotes, all of whom were non-obese.
Thus, Tyr221Cys is found at significantly higher frequency in
a population of UK Caucasians subjects with early-onset obe-
sity than in unselected UK Caucasian controls (5/538 versus
4/5152, Chi-Square 22.4, p < 0.001). The Tyr221Cys variant
was not found in 1132 obese French Caucasian subjects (597
morbidly obese adults [BMI 47.56 7.53] and 535 obese children
[BMI sds = 4.376 1.31\), nor in 723 lean French Caucasian sub-
jects (BMI 23.29 6 2.74). These observations suggest that
Tyr221Cys is likely to be a rare variant in Caucasian populations.
Does the Tyr221Cys mutation in b-MSH cosegregate
with obesity in families?
To examine whether this variant was linked to obesity/over-
weight in families, first-degree relatives were contacted, and
those who agreed to be studied were examined and genotyped
(Figure 1B). Thirteen relatives were heterozygotes for Tyr221Cys,
11 of which were obese, two overweight, and none lean. Five rel-
atives were wild-type, three of which were obese and two lean.
Thus, in total, in these families, 0/20 Tyr221Cys carriers and 2/5
wild-type subjects were lean.
Tyr221Cys b-MSH mutation alters three-dimensional
structure of b-MSH, binding, and signaling
through MC4R
Tyr221 is a highly conserved residue, being present in the
b-MSH sequence of species from teleost fish through to mam-
mals (accession numbers: Zebrafish NP_852103, Chicken
BAA34366, Mouse P01193, Rat AAA41903, Human P01189).
A tyrosine is also present in the equivalent position in all melano-
cortins from all mammalian species. To determine whether
Tyr221 is necessary for the normal three-dimensional struc-
ture of b-MSH, we undertook NMR studies of wild-type and a
mutant peptide analog replacing Tyr221 with Serine (to avoid in-
termolecular disulfide formation common with Cys-containing






Nonsynonymous SNPs & insertion
Leu37Phe 1 0
9 bp insertion (c.297-298insAGCAGCGGC) 51 (9.48%) 28 (9.33%)
Pro132Ala 1 0
His143Gln 1 1 (0.33%)
Ala195Thr 1 0
Glu214Gly 8 (1.49%) 2 (0.67%)
Tyr221Cys 5 (0.93%) 1 (0.33%)




Ala195Ala 4 (0.74%) 1 (0.33%)
Leu116Leu 8 (1.49%) 7 (2.33%)
Synonymous and nonsynonymous variants in severely obese children and con-
trols.CELL METABOLISM : FEBRUARY 2006
b-MSH mutations and human obesityFigure 1. Identification and characterization of Tyr221Cys b-MSH mutation
A) Structure of POMC and location of rare missense mutations.
B) Cosegregation of Tyr221Cys b-MSH mutation with obesity (black symbols) and overweight (gray symbols) in families. Genotype (N = wild-type allele, M = mutant allele)
and BMI sds is denoted. In adults, overweight defined as BMI 25–30 kg/m2, obesity as BMI > 30 kg/m2. In children, overweight defined as >91st and obesity as >99th per-
centile for age-adjusted BMI. Arrows indicate the proband of each family.
C) Comparison of the Chemical Shift Index (CSI = experimental chemical shift—consensus random coil chemical shift) values between wild-type and mutant b-MSH.
Throughout the segment Arg-Met-Glu-His-Phe-Arg-Trp, the CSIs for both peptides were indicating the presence of turns (values ranging from 20.01 to 20.24). For the
receptor binding motif, His-Phe-Arg-Trp, both wild-type and mutant peptides gave approximately identical values. However, for the Arg-Met residues following the mu-
tation, but preceding the receptor binding motif, the wild-type sequence showed a significantly greater tendency to form turns relative to the mutant.
D) [Cys5] b-MSH binds to MC4R with lower affinity than b-MSH. Whole HEK293 cells stably expressing wild-type MC4R were exposed to tracer amounts of [125I]NDP-MSH,
and the ability of increasing concentrations of b-MSH or [Cys5] b-MSH to inhibit radio-ligand binding was measured as described previously. Data are expressed as a per-
centage of maximum counts of [125I]NDP-MSH binding to MC4R. Each point represents the mean (6SEM) of four independent experiments in triplicate.
E) [Cys5] b-MSH has a markedly reduced ability to stimulate production of cAMP. Graphs indicate responses of wild-type, mutant, and control constructs to a logarithmic
increase in b-MSH concentration. cAMP/Luciferase reporter assays were performed as described previously (Yeo et al., 2003). Open symbols denote mock transfected
controls. Each point represents the mean (6SEM) of eight independent experiments performed in quadruplicate.peptides). Chemical Shift Index (CSI) values were used to probe
average structural properties (Mielke and Krishnan, 2004; Wish-
art et al., 1992). Compared to wild-type b-MSH, the mutation re-
sulted in a significantly reduced helical turn propensity for two of
the three residues between the mutation site and the His-Phe-
Arg-Trp receptor binding motif (see Figure 1C and Supplemental
Data available with this article online). When compared to wild-
type b-MSH, a synthetic peptide incorporating the Tyr221Cys
mutation showed reduced binding to MC4R stably expressed
in HEK293 cells (Figure 1D) (IC50 of mutant b-MSH = 797.1 6
261.0 nM compared to 67.2 6 43.0 nM of wt b-MSH, p =
0.006). Consistent with these findings, the addition of wild-
type b-MSH led to a dose-dependent increase in cAMP accu-
mulation in HEK293 cells transiently expressing MC4R, while
Tyr221Cys generated significantly less cAMP (Figure 1E)
(EC50 mutant b-MSH = 1.95 nM compared to 0.1 nM of wt b-
MSH, p = 0.04).CELL METABOLISM : FEBRUARY 2006Clinical phenotype of subjects with the Tyr221Cys
mutation in b-MSH
To establish whether obese children carrying the b-MSH muta-
tion were hyperphagic, we admitted six children heterozygous
for Tyr221Cys b-MSH (five probands and one relative) to the Ad-
denbrooke’s Hospital Clinical Research Facility. The six children
underwent an ad libitum test breakfast. Ad libitum caloric intake,
expressed per kg lean mass, was markedly increased com-
pared to normal weight control children (Figure 2A) and similar
to that seen in subjects heterozygous for MC4R mutations (Far-
ooqi et al., 2003). Basal metabolic rate of affected subjects was
not significantly different from that predicted using age- and
gender-specific equations (data not shown). In order to deter-
mine whether obese children carrying the b-MSH mutation
had other phenotypic similarities to children with known defects
in MC4R signalling, we assessed body composition using stan-
dard procedures (Farooqi et al., 2003). The children with the137
S H O R T A R T I C L EFigure 2. Phenotypes of subjects with mutations in POMC
A) Food intake at an 18MJ ad libitum test meal compared to normal weight controls. Food intake is expressed per kg lean body mass measured by dual energy X-ray
absorptiometry (DXA) to allow comparison between subjects of different ages (Farooqi et al., 2003) ***p < 0.001.
B) Height SDS in children with the Tyr221Cys mutation in b-MSH compared to heterozygotes for MC4R mutations and controls of comparable age and degree of obesity.
**p < 0.01
C) Fat-free mass (FFM) measured by DXA in children with the Tyr221Cys mutation in b-MSH compared to heterozygotes for MC4R mutations and controls of comparable
age and degree of obesity (unpublished data). **p < 0.01b-MSH mutation more closely resembled MC4R heterozygotes
than equivalently obese children (with normal MC4R and POMC
sequence) in terms of accelerated linear growth and increased
fat-free mass (Figures 2B and 2C).
Characterization of a mutation in a-MSH
As described above, one UK Caucasian proband was found to
have a missense mutation (His143Gln) in a-MSH (Figure 1A).
However, this was also present in one of the 300 UK Caucasian
controls. The grandfather of the proband carried the mutation
and was obese, but the transmitting parent was lean (Figure 3A).
The mutation replaces a highly conserved residue within the
classical His-Phe-Arg-Trp receptor binding motif of the melano-138cortins and would be expected to impair function. Consistent
with this, a synthetic mutant peptide has marked reduced affin-
ity for the MC4 receptor (Figure 3B) (IC50 of mutant a-MSH =
1624 6 624 nM compared to 15.2 6 14.0 nM of wt a-MSH,
p < 0.0001). The His143Gln mutant a-MSH also had reduced
ability to stimulate cAMP generation from MC4R (Figure 3C)
with a reduced maximal response, although the EC50 was not
significantly different from wild-type (EC50 mutant a-MSH =
3.8 nM compared to 2.2 nM of wt a-MSH, p = ns). Thus, while
heterozygous disruption of a-MSH function may play a contribu-
tory role in the obesity of the proband, the presence of this
mutation in a lean transmitting family member implies that it is
insufficient, in itself, to fully explain the obese phenotype.Figure 3. His143Gln a-MSH mutation
A) Cosegregation of His143Gln a-MSH mutation with obesity (black symbols). N = wild-type allele, M = Mutant allele.
B) [Gln6] a-MSH binds to MC4R with lower affinity than a-MSH (methods as in Figure 1D). Data is expressed as a percentage of maximum counts of [125I]NDP-MSH binding
to MC4R. Each point represents the mean (6SEM) of four independent experiments in triplicate.
C) [Gln6] a-MSH has a markedly reduced ability to stimulate production of cAMP (methods as in Figure 1E). Open symbols denote mock-transfected controls. Each point
represents the mean (6SEM) of eight independent experiments performed in quadruplicate.CELL METABOLISM : FEBRUARY 2006
b-MSH mutations and human obesityDiscussion
Tyr221Cys mutation in b-MSH is associated
with human early-onset obesity
These studies provide compelling evidence that b-MSH is likely
to be a physiologically relevant, endogenous ligand for the
MC4R in humans. Firstly, the Tyr221Cys variant is enriched in
a population of UK Caucasian subjects with early-onset obesity
compared to its background prevalence in the UK population.
The overrepresentation of this mutation in obese subjects is
supported by independent studies in a German population (Bie-
bermann et al., personal communication). The fact that we did
not find this variant at all in a large French population suggests
that this variant may have arisen relatively recently in European
ancestry.
Further support for the importance of b-MSH in energy ho-
meostasis is provided by our previous observation of an associa-
tion of a cleavage site mutation affecting b-MSH with obesity
although, in contrast with Tyr221Cys, that mutation resulted in
the production of a peptide with the potential to interfere with sig-
naling at the MC4R in a dominant-negative manner (Challis et al.,
2002). It is unlikely that Tyr221Cys would result in a dominant-
negative interference with wild-type b-MSH so, in this case,
one would have to hypothesize that this mutation simply reduces
the amount of b-MSH tone at the MC4R and that this in itself
is sufficient to predispose to obesity. The plausibility of such
a model is supported by the increased prevalence of obesity
and overweight in carriers of POMC null mutations (Krude et al.,
2003), a finding which we ourselves have recently replicated in
a further large pedigree (unpublished data).
It is important to note that the Tyr221Cys mutation is unlikely
to be a highly penetrant cause of monogenic obesity, but that
apparent enrichment in obese populations is likely to occur be-
cause it is an allele that increases the risk of obesity. Our reasons
for stating this include (1) the fact that human and murine hetero-
zygotes for null mutations in POMC show a propensity to in-
creased adiposity but are not all frankly obese (Krude et al.,
2003) (and unpublished data) and (2) the fact that some carriers
of the Tyr221Cys b-MSH mutation are not obese.
Both a-MSH and b-MSH influence melanocortinergic
tone in humans
It is noteworthy that the vast majority of the literature concerning
the POMC system and energy homeostasis focuses on the pos-
sible role of a- rather than b-MSH as the endogenous ligand (Coll
et al., 2004; Cone, 2005). This is understandable, as in rodents
the N-terminal cleavage site necessary for the generation of
b-MSH is absent. In contrast, b-MSH has been established to
be present in the human hypothalamus (Bertagna et al., 1986).
Interestingly, we found a missense mutation in a-MSH in a single
proband, which had a major deleterious effect on its function.
However, this variant was found in one lean family member
and one lean unrelated control. While it is likely that this variant
is contributing to the obesity of the proband, it is notable that our
human genetic studies provide more compelling evidence for
a specific role for b-MSH than a-MSH in the control of human
energy balance. Finally, the similarities in clinical phenotype be-
tween obese children carrying the Tyr221Cys b-MSH mutation
and those with MC4R mutations (Farooqi et al., 2003) suggest
that both mutations are affecting shared physiological path-
ways. In conclusion, b-MSH is likely to be an important andCELL METABOLISM : FEBRUARY 2006physiologically relevant endogenous ligand for the human
MC4R. These findings illustrate how human genetics can pro-
vide insights into the important physiological roles of particular
species-restricted peptides that are not obtainable through
the study of rodent models.
Experimental procedures
Human genetics and cohorts
Five hundred and thirty-eight UK Caucasian subjects with severe early-onset
obesity were screened using a combination of direct nucleotide sequencing
and denaturing high-performance liquid chromatography (Transgenomic
WAVE DNA fragment analysis) as previously described (Challis et al.,
2002). Subjects were recruited as part of the Genetics of Obesity Study
(GOOS) cohort (O’Rahilly et al., 2003), and mutations in leptin, leptin receptor,
and MC4R had been excluded by direct nucleotide sequencing. The mean
BMI SDS of this group was 3.8 6 0.9, mean age of onset < 5 years. BMI
sds was calculated using age- and gender-specific UK population data
(Cole et al., 1995).
For comparison of allele frequency, 300 randomly selected non-obese
adult controls from the MRC Ely Study (Wareham et al., 2000) were screened
using the same techniques.
Genotyping of the Tyr221Cys variant was performed in 5000 subjects from
a UK Caucasian population-based cohort, the EPIC-Norfolk study (Khaw
et al., 2001). These subjects were screened using a custom-made assay
based on TaqMan chemistry (Applied Biosystems, Warrington, United King-
dom).
Genotyping of the Tyr221Cys variant was also performed in two groups of
French obese subjects: 597 morbidly obese adults (BMI 47.5 67.53), 535
obese children (BMI sds = 4.37 6 1.31) and also in 723 lean controls (BMI
23.29 6 2.74). These subjects were genotyped using a FRET (Fluorescence
Resonance Energy Transfer) based assay using the LightTyper technology
(Roche, Meylan, France and Mannheim, Germany) as previously reported
(Meyre et al., 2005). Probes for LightTyper were synthesized by TIB Molbiol
Syntheselabor Germany.
NMR studies
Two-dimensional 1H NMR (2D-NOESY and 2D-TOCSY) performed on pep-
tides corresponding to the b-MSH segment of POMC was used to assign
chemical shifts in both wild-type and a mutant with a Tyr221Ser mutation.
Ser was used instead of Cys since, at NMR concentrations, free -SH groups
tend to form disulfides. For flexible peptides, a negative CSI indicates a turn
or helical structure and a positive CSI indicates the presence of extended,
b sheet conformers (Mielke and Krishnan, 2004; Wishart et al., 1992). See
Supplemental Data for additional experimental procedures.
Competitive binding studies
Whole HEK293 cells stably expressing wild-type MC4R were exposed to
tracer amounts of [125I]NDP-MSH, and the ability of increasing concentra-
tions of b-MSH or [Cys5] b-MSH to inhibit radioligand binding was measured
as described previously (Yeo et al., 2003). All wild-type and mutant peptides
were obtained from Bachem.
Receptor activation studies
HEK293 cells were transiently transfected with wt MC4R and cotransfected
with a cAMP-dependent luciferase reporter construct. cAMP/Luciferase re-
porter assays were performed as described previously (Yeo et al., 2003).
Physiological studies
Measurements of food intake and body composition were undertaken after
appropriate informed consent and using protocols previously described (Far-
ooqi et al., 2003).
Supplemental data
Supplemental data include text and one table and can be found with the
article online at http://www.cellmetabolism.org/cgi/content/full/3/2/135/
DC1/.139
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